organizer founding sponsor co-sponsors · gemcitabine (nab-p/g) vs gemcitabine (g) for surgically...
TRANSCRIPT
TIME SUNDAY/JUNE 2
10.30 ▶ Arrival & Registration
12.00 ▶ Lunch
13.00 ▶ Welcome
13.15 ▶ Virtual Meeting Session I
15.00 ▶ Coffee Break
15.30 ▶ Virtual Meeting Session II
17.30 ▶ End of Scientific Program
TIME TUESDAY/JUNE 408.30 ▶ Highlights previous day
08.35 ▶ Virtual Meeting Session VII
10.00 ▶ Coffee Break
10.30 ▶ Virtual Meeting Session VIII
12.00 ▶ Lunch
13.15 ▶ Virtual Meeting Session IX
14.00 ▶ Live in Chicago
15.00 ▶ Coffee Break
15.30 ▶ Virtual Meeting Session X
17.30 ▶ End of Scientific Program
TIME MONDAY/JUNE 308.30 ▶ Highlights previous day
08.35 ▶ Virtual Meeting Session III
10.00 ▶ Coffee Break
10.30 ▶ Virtual Meeting Session IV
12.00 ▶ Lunch
13.15 ▶ Virtual Meeting Session V
14.00 ▶ Live in Chicago
15.00 ▶ Coffee Break
15.30 ▶ Virtual Meeting Session VI
17.30 ▶ End of Scientific Program
▶ BBQ
TIME WEDNESDAY/JUNE 508.30 ▶ Highlights previous day
08.35 ▶ Virtual Meeting Session XI
10.00 ▶ Coffee Break
10.30 ▶ Virtual Meeting Session XII
11.45 ▶ Practice Changing Highlights ASCO Annual Meeting 2019
12.00 ▶ Lunch
13.15 ▶ Departure
ASCO® and American Society of Clinical Oncology® are registered trademarks of the American Society of Clinical Oncology, Inc. Used with permission. This is not an ASCO sponsored product, event or publication. The mention of any company, product, service, or therapy does not constitute an endorsement of any kind by ASCO.
Organizer Founding Sponsor Co-Sponsors
Sunday / June 2, 2019 Educational or Abstract Title Presenter Duration Link VM
10:00 SC & Organizer Meeting
10:30
Arrival & Registration
Attendees
12:00-13:00 Lunch
13:00-13:15 Welcome SC
13:15-15:00
Chairmen
VM Session I - 1h45
Abstract #
Chair: J. Beyer Edu Uses for PSMA Diagnostics and Therapeutic Approaches in Localized Disease: A Urologist's Perspective Robert Evan Reiter 15min https://meetinglibrary.asco.org/record/167970/video
Chair: J. Beyer 5001 Short hormonotherapy (HT) associated with radiotherapy (RT) as salvage treatment for metastatic free
survival (MFS) after radical prostatectomy (RP): Update at 9 years of the GETUG-AFU 16 phase III randomized Christian Carrie summary by Jörg Beyer, PPT
Chair: J. Beyer 5007 Decreased fracture rate by mandating bone-protecting agents in the EORTC 1333/PEACE III trial comparing
enzalutamide and Ra223 versus enzalutamide alone: An interim safety analysis.Bertrand F. Tombal 11min https://meetinglibrary.asco.org/record/172905/video
Chair: J. Beyer 5008 Alliance A031201: A phase III trial of enzalutamide (ENZ) versus enzalutamide, abiraterone, and prednisone
(ENZ/AAP) for metastatic castration resistant prostate cancer (mCRPC)Michael J. Morris 11min https://meetinglibrary.asco.org/record/172903/video
Chair: J. Beyer 5005 TOPARP-B: A phase II randomized trial of the poly(ADP)-ribose polymerase (PARP) inhibitor olaparib for
metastatic castration resistant prostate cancers (mCRPC) with DNA damage repair (DDR) alterations.Joaquin Mateo 12min https://meetinglibrary.asco.org/record/172904/videoChair: N. Pless / U.
Petrausch Eud What’s the Role for Immunotherapy With and Without Chemotherapy in Oncogene Mutated NSCLC? Corey J. Langer 19min https://meetinglibrary.asco.org/record/167455/videoChair: N. Pless / U.
Petrausch Edu The Next Frontier: Understanding and Overcoming Resistance to Targeted Therapy and Immunotherapy Pradnya Dinkar Patil16min https://meetinglibrary.asco.org/record/167441/video
15:00-15:30 Coffee Break
15:30-17:30
Chairmen
VM Session II - 2h
Abstract #
Chair: U. Gueller / D.
HelblingEdu Systemic Therapy for Anal Squamous Cell Carcinoma Cathy Eng 11min https://meetinglibrary.asco.org/record/167357/video
Chair: U. Gueller / D.
HelblingEdu Cancer Prevention Through Human Papillomavirus Vaccination Joes Paflesky 15min https://meetinglibrary.asco.org/record/167366/videoChair: T. Ruhstaller / P.
Weder Debate Complete Axillary Nodal Dissection Is Indicated for All Patients With Positive Nodes Prior to Neoadjuvant Systemic Therapy Neumann 15min https://meetinglibrary.asco.org/record/168039/videoChair: T. Ruhstaller / P.
Weder Debate
Complete Axillary Nodal Dissection Is Indicated for All Patients With Positive Nodes Prior to Neoadjuvant
Systemic Therapy Bedrosian 7min https://meetinglibrary.asco.org/record/167342/videoChair: T. Ruhstaller / P.
Weder Debate
Complete Axillary Nodal Dissection Is Indicated for All Patients With Positive Nodes Prior to Neoadjuvant
Systemic Therapy Mamounas 7min https://meetinglibrary.asco.org/record/167417/video
Chair: S. Hofer Suggestions Sarcoma Efficacy of low dose pazopanib in advanced soft tissue sarcoma (STS)Abstr e22555 Silvia Hofer 10min ppt presentation by Slivia Hofer
17:30 End of Scientific Program
19:00 Dinner Buffet
Monday / June 3, 2019 Abstract Title Presenter Duration Link VM Start VM at Link Abstract Comments
8:30-8:35
Practice Changing Highlights day 1 &
Outlook
8:35-10:00
Chairmen
VM Session III - 1h25
Abstract #
Ulrich Güller/Daniel Helbling 3501Prospective pooled analysis of four randomized trials investigating duration of adjuvant (adj) oxaliplatin-
based therapy (3 vs 6 months {m}) for patients (pts) with high-risk stage II colorectal cancer (CC).Timothy Iveson 12 min https://meetinglibrary.asco.org/record/171153/video
Ulrich Güller/Daniel Helbling Short Educational IDEA 3 vs 6 m of chemo Ulrich Güller 10 min
Ulrich Güller/Daniel Helbling 3504FOxTROT: an international randomised controlled trial in 1052 patients (pts) evaluating neoadjuvant
chemotherapy (NAC) for colon cancer.Matthew T. Seymour 12 min https://meetinglibrary.asco.org/record/171160/video
Ulrich Güller/Daniel Helbling 3508Updated results of TRIBE2, a phase III, randomized strategy study by GONO in the first- and second-line
treatment of unresectable mCRC.Chiara Cremolini 12 min https://meetinglibrary.asco.org/record/171184/video
Ulrich Güller/Daniel Helbling LBA 4Olaparib as maintenance treatment following first-line platinum-based chemotherapy (PBC) in patients
(pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC): Phase III POLO trial.Hedy L. Kindler 13 min https://meetinglibrary.asco.org/record/174488/video
10:00-10:30 Coffee Break
10:30-12:00
Chairmen
VM Session IV - 1h30
Abstract #
Ulrich Güller/Daniel Helbling 4000APACT: phase III, multicenter, international, open-label, randomized trial of adjuvant nab-paclitaxel plus
gemcitabine (nab-P/G) vs gemcitabine (G) for surgically resected pancreatic adenocarcinoma.Margaret A Tempero 10 min https://meetinglibrary.asco.org/record/173181/video
Ulrich Güller/Daniel Helbling 4003
ABC-06 | A randomised phase III, multi-centre, open-label study of Active Symptom Control (ASC) alone or
ASC with oxaliplatin / 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced /
metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem)
chemotherapy.
Angela Lamarca 12 min https://meetinglibrary.asco.org/record/173183/video
Ulrich Güller/Daniel Helbling 4004Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for
second line therapy in advanced hepatocellular carcinoma (HCC).Richard S Finn https://meetinglibrary.asco.org/record/173190/video
Ulrich Güller/Daniel Helbling LBA4007Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or
gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study.Joseph Tabernero 13 min https://meetinglibrary.asco.org/record/173187/video
Ulrich Güller/Daniel Helbling 4006Optimizing chemotherapy for frail and elderly patients (pts) with advanced gastroesophageal cancer
(aGOAC): The GO2 phase III trial. Peter S HallPeter S Hall 12 min https://meetinglibrary.asco.org/record/173850/video
Ulrich Güller/Daniel Helbling 4002A multicenter randomized controlled trial to evaluate the efficacy of surgery vs. radiofrequency ablation
for small hepatocellular carcinoma (SURF trial).Namiki Izumi 12 min https://meetinglibrary.asco.org/record/174776/video
12:00-13:15 Lunch
13:15-14:00
Chairmen
VM Session V - 45'
Abstract #
Christoph Driessen Educational Octagenarians with Multiple Myeloma Sonja Zweegman 15 min https://meetinglibrary.asco.org/record/167897/video
Christoph Driessen 8003Phase 3 randomized study of daratumumab (DARA) + bortezomib/thalidomide/dexamethasone (D-VTd) vs
VTd in transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM): CASSIOPEIA Part 1 results.Philippe Moreau 12 min https://meetinglibrary.asco.org/record/172374/video
Christoph Driessen 8005Efficacy and safety of the randomized, open-label, non-inferiority, phase 3 study of subcutaneous (SC)
versus intravenous (IV) daratumumab (DARA) administration in patients (pts) with relapsed or refractory
multiple myeloma (RRMM): COLUMBA.
Maria-Victoria Mateos 12 min https://meetinglibrary.asco.org/record/174838/video
14:00-15:00 Live Session
Moderation:
Daniel Helbling Dr. med. Stefan Zimmermann Neoadjuvant Therapy: Should Medical Oncologists Go First? Jordan D. Berlin, MD, FASCO / Vanderbilt University
Daniel Helbling Dr. med. Stefan Zimmermann
Updated results of TRIBE2, a phase III, randomized strategy study by GONO in the first- and second-line
treatment of unresectable mCRC Chiara Cremolini, MD / Department of Translational Research and New Technologies in Medicine and Surgery, Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana
Ulrich Güller Dr. med. Stefan Zimmermann
APACT: phase III, multicenter, international, open-label, randomized trial of adjuvant nab-paclitaxel plus
gemcitabine (nab-P/G) vs gemcitabine (G) for surgically resected pancreatic adenocarcinoma Margaret A. Tempero, M.D. / Director, UCSF Pancreas Center
15:00-15:30 Coffee Break15:30-17:30
Chairmen
VM Session VI - 2h
Abstract #
Silvia Hofer LBA3ANNOUNCE: A randomized, placebo (PBO)-controlled, double-blind, phase (Ph) III trial of doxorubicin (dox)
+ olaratumab versus dox + PBO in patients (pts) with advanced soft tissue sarcomas (STS).William D. Tap 15 min https://meetinglibrary.asco.org/record/174690/video
Silvia Hofer Poster Discussion Building the Evidence for Immunotherapy in Sarcoma Thierry Alcindor 5 min https://meetinglibrary.asco.org/record/175573/video
Jörg Beyer Plenary sessionOverall survival (OS) results of a phase III randomized trial of standard-of-care therapy with or without
enzalutamide for metastatic hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an
ANZUP-led international cooperative group tria
Christopher Sweeney 20 min https://meetinglibrary.asco.org/record/174531/video
Jörg Beyer Plenary session Discussion ENZAMET Tanya B. Dorff 15 min https://meetinglibrary.asco.org/record/178202/video
Thomas Ruhstaller DebateComplete Axillary Nodal Dissection Is Indicated for All Patients With Positive Nodes Prior to Neoadjuvant
Systemic Therapy Heather B. Neuman 15 min https://meetinglibrary.asco.org/record/168039/video
Thomas Ruhstaller DebateComplete Axillary Nodal Dissection Is Indicated for All Patients With Positive Nodes Prior to Neoadjuvant
Systemic Therapy Isabelle Bedrosian 7 min https://meetinglibrary.asco.org/record/167342/video
Thomas Ruhstaller DebateComplete Axillary Nodal Dissection Is Indicated for All Patients With Positive Nodes Prior to Neoadjuvant
Systemic Therapy Eleftherios P. Mamounas 7 min https://meetinglibrary.asco.org/record/167417/video
Ulf Petrausch Case Case 3: Managing Immunotherapy in Patients with Renal Insufficiency (PD-L1 Low) Melissa Lynne Johnson 60 min https://meetinglibrary.asco.org/record/167469/video
17:30 End
19:30 Apéro & Dinner Buffet
Tuesday / June 4, 2019 Abstract Title Presenter Duration Link VM
8:30-8:35 Practice Changing Highlights day 2 & Outlook
8:35-10:00Chairmen VM Session VII - 1h25Abstract #
Ulf Petrausch 6000Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab
(pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell
carcinoma (R/M HNSCC).
Danny Rischin 12 min https://meetinglibrary.asco.org/record/171051/video
Ulf Petrausch Wolfram: Erklärung Immumo-Scores für Onkologen 10 min
Ulf Petrausch 9001Phase III randomized trial comparing gefitinib to gefitinib with pemetrexed-carboplatin
chemotherapy in patients with advanced untreated EGFR mutant non-small cell lung cancer
(gef vs gef+C).
Vanita Noronha 13 min https://meetinglibrary.asco.org/record/173366/video
Ulf Petrausch Chemotherapy and Antiangiogenic Therapy in 2019: Who Needs It? 8 min https://meetinglibrary.asco.org/record/174735/video
Ulf Petrausch 9004Capmatinib (INC280) in METΔex14-mutated advanced non-small cell lung cancer (NSCLC):
Efficacy data from the phase II GEOMETRY mono-1 study.Juergen Wolf 13 min https://meetinglibrary.asco.org/record/173357/video
Ulf Petrausch New Drugs and Resistance: Have We MET Expectations? 6 min https://meetinglibrary.asco.org/record/174909/video
Ulf Petrausch 9007 Antitumor activity of TAK-788 in NSCLC with EGFR exon 20 insertions. Pasi A. Janne 13 min https://meetinglibrary.asco.org/record/174631/video
10:00-10:30 Coffee Break
10:30-12:00Chairmen VM Session VIII - 1h30Abstract #
Thomas Ruhstaller 500
Neoadjuvant trastuzumab (H), pertuzumab (P), and chemotherapy versus trastuzumab
emtansine (T-DM1) and P in human epidermal growth factor receptor 2 (HER2)-positive
breast cancer (BC): Final outcome results from the phase III KRISTINE study. Hurvitz https://meetinglibrary.asco.org/record/172055/video
Thomas Ruhstaller 501
Docetaxel, trastuzumab, pertuzumab versus trastuzumab emtansine as neoadjuvant
treatment of HER2-positive breast cancer: Results from the Swedish PREDIX HER2 trial
identifying a new potential de-escalation standard? Jonas Bergh https://meetinglibrary.asco.org/record/172373/video
Thomas Ruhstaller 502
HER2 heterogeneity as a predictor of response to neoadjuvant T-DM1 plus pertuzumab:
Results from a prospective clinical trial Otto Metzger Filho https://meetinglibrary.asco.org/record/174997/video
Thomas Ruhstaller Disc Anti-HER2 Therapy at the Forefront: Stepping Closer to De-escalation Pelgram https://meetinglibrary.asco.org/record/177343/video
Jörg Beyer 4500Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for
metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC
intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study.
Brian I. Rini 12 min https://meetinglibrary.asco.org/record/171839/video
Jörg Beyer Discussant Evolving Front-Line Therapy in Metastatic Renal Cell Carcinoma Rana McKay 12 min https://meetinglibrary.asco.org/record/175123/video
12:00-13:15 Lunch
13:15-14:00Chairmen VM Session IX - 45'Abstract #
Jörg Beyer 4502Randomized, double-blind phase III study of pazopanib versus placebo in patients with
metastatic renal cell carcinoma who have no evidence of disease following
metastasectomy: A trial of the ECOG-ACRIN cancer research group (E2810).
Leonard Joseph Appleman 12 min https://meetinglibrary.asco.org/record/171840/video
Jörg Beyer 4503CALGB 90601 (Alliance): Randomized, double-blind, placebo-controlled phase III trial
comparing gemcitabine and cisplatin with bevacizumab or placebo in patients with
metastatic urothelial carcinoma.
Jonathan E. Rosenberg 12 min https://meetinglibrary.asco.org/record/171835/video
Silvia Hofer 2000Second interim and first molecular analysis of the EORTC randomized phase III intergroup
CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without
1p/19q codeletion�
Martin J. Van Den Bent
14:00-15:00 Live Session
Moderation:
Ulf Petrausch Dr. med. Stefan Zimmermann
What Do I Do: Immune Toxicity? Overview of Immunotherapy Toxicity? Oncologist
Overview Mario Sznol, MD / Yale School of Medicine and Smilow Cancer Center, Yale New Haven Hospital
J. Beyer Dr. med. Stefan Zimmermann
“Treatment choices in first-line metastatic renal cancer and perioperative/metastatic
bladder cancer”? PD Dr. med. Aurelius Omlin / KSSG
cancelled in last minute:
Ulrich Güller Dr. med. Stefan Zimmermann POSTER DISCUSSION SESSION: Gastrointestinal (Colorectal) Cancer Fotios Loupakis, MD, PhD / Istituto Toscano Tumori
15:00-15:30 Coffee Break
15:30-17:30Chairmen VM Session X - 2hAbstract #
Patrik Weder 5500
A randomized phase 3 trial of paclitaxel (P) plus carboplatin (C) versus paclitaxel plus
ifosfamide (I) in chemotherapy-naive patients with stage I-IV, persistent or recurrent
carcinosarcoma of the uterus or ovary: An NRG oncology trial.
Matthew A. Powell 12 min https://meetinglibrary.asco.org/record/173464/video
Patrik Weder 5502Phase 2, two-group, two-stage study of avelumab in patients (pts) with microsatellite stable
(MSS), microsatellite instable (MSI), and polymerase epsilon (POLE) mutated
recurrent/persistent endometrial cancer (EC).
Panagiotis A. Konstantinopoulos 12 min https://meetinglibrary.asco.org/record/173434/video
Patrik Weder 5503Results from neoadjuvant chemotherapy followed by surgery compared to chemoradiation
for stage Ib2-IIb cervical cancer, EORTC 55994.Gemma Kenter 12 min https://meetinglibrary.asco.org/record/173453/video
Patrik Weder 5506Olaparib monotherapy versus (vs) chemotherapy for germline BRCA-mutated (gBRCAm)
platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase III SOLO3 trial.Richard T. Penson 12 min https://meetinglibrary.asco.org/record/173435/video
Patrik Weder 5505Combination of niraparib and bevacizumab versus niraparib alone as treatment of
recurrent platinum-sensitive ovarian cancer. A randomized controlled chemotherapy-free
study—NSGO-AVANOVA2/ENGOT-OV24.
Mansoor Raza Mirza 12 min https://meetinglibrary.asco.org/record/173447/video
Brigitta Baumert 11001STRASS (EORTC 62092): A phase III randomized study of preoperative radiotherapy plus
surgery versus surgery alone for patients with retroperitoneal sarcoma.Sylvie Bonvalot 12 min https://meetinglibrary.asco.org/record/174255/video
17:30 End
19:00 Dinner Buffet Terrace
Wednesday / June 5, 2019 Abstract Title Presenter Duration Link VM
8:30-8:35 Practice Changing Highlights day 2 & Outlook
8:35-10:00Chairmen VM Session XI - 1h25Abstract #
Weder Patrik 1002
Neratinib + capecitabine versus lapatinib + capecitabine in patients with HER2+ metastatic breast cancer
previously treated with ≥ 2 HER2-directed regimens: Findings from the multinational, randomized, phase III NALA
trial.
Cristina Saura 12 min https://meetinglibrary.asco.org/record/170932/video
Weder Patrik 1003
IMpassion130: updated overall survival (OS) from a global, randomized, double-blind, placebo-controlled, Phase III
study of atezolizumab (atezo) + nab-paclitaxel (nP) in previously untreated locally advanced or metastatic triple-
negative breast cancer (mTNBC).
Peter Schmid 12 min https://meetinglibrary.asco.org/record/170934/video
Ruhstaller Thomas 1005
Capivasertib (AZD5363) plus fulvestrant versus placebo plus fulvestrant after relapse or progression on an
aromatase inhibitor in metastatic ER-positive breast cancer (FAKTION): A randomized, double-blind, placebo-
controlled, phase II trial.
Robert Hugh Jones 12 min https://meetinglibrary.asco.org/record/170933/video
Ruhstaller thomas 1007
A randomized phase II study of palbociclib plus exemestane with GNRH agonist versus capecitabine in
premenopausal women with hormone receptor-positive metastatic breast cancer (KCSG-BR 15-10,
NCT02592746).
Yeon Hee Park 12 min https://meetinglibrary.asco.org/record/174497/video
Ruhstaller Thomas 1008Phase III MONALEESA-7 trial of premenopausal patients with HR+/HER2− advanced breast cancer (ABC) treated
with endocrine therapy ± ribociclib: Overall survival (OS) results.Sara A. Hurvitz 12 min https://meetinglibrary.asco.org/record/174827/video
10:00-10:30 Coffee Break
10:30-11:45Chairmen VM Session XII - 1h30Abstract #
Ulrich Güller / Daniel Helbling 4004Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line
therapy in advanced hepatocellular carcinoma (HCC).Richard S Finn 12 min https://meetinglibrary.asco.org/record/173190/video
Ulrich Güller / Daniel Helbling Short Presentation HCC and IDEA Güller PPT, 3 min
Ulrich Güller / Daniel Helbling 4006Optimizing chemotherapy for frail and elderly patients (pts) with advanced gastroesophageal cancer (aGOAC): The
GO2 phase III trial. Peter S HallPeter S Hall 12 min https://meetinglibrary.asco.org/record/173850/video
Ulrich Güller / Daniel Helbling 4002A multicenter randomized controlled trial to evaluate the efficacy of surgery vs. radiofrequency ablation for small
hepatocellular carcinoma (SURF trial).Namiki Izumi 12 min https://meetinglibrary.asco.org/record/174776/video
11:45
Wrap Up (Practice Changing Highlights) & Good
Bye
12:00-13:15 Lunch